Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Interest & Investment Income (2019 - 2025)

Black Diamond Therapeutics' Interest & Investment Income history spans 5 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 109.56% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $4.1 million, up 86.11%, while the annual FY2025 figure was $4.1 million, 86.11% up from the prior year.
  • Interest & Investment Income reached $1.2 million in Q4 2025 per BDTX's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $1.2 million in Q4 2025 to a low of $464000.0 in Q2 2024.
  • Average Interest & Investment Income over 3 years is $829000.0, with a median of $776000.0 recorded in 2021.
  • Peak YoY movement for Interest & Investment Income: plummeted 33.22% in 2021, then skyrocketed 140.95% in 2025.
  • A 3-year view of Interest & Investment Income shows it stood at $776000.0 in 2021, then fell by 27.19% to $565000.0 in 2024, then soared by 109.56% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Interest & Investment Income are $1.2 million (Q4 2025), $1.2 million (Q3 2025), and $1.1 million (Q2 2025).